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Abstract
HSV-1 is the leading cause of sporadic encephalitis in humans. HSV infection of susceptible 129S6 mice results in fatal
encephalitis (HSE) caused by massive inflammatory brainstem lesions comprising monocytes and neutrophils. During
infection with pathogenic microorganisms or autoimmune disease, IgGs induce proinflammatory responses and recruit
innate effector cells. In contrast, high dose intravenous immunoglobulins (IVIG) are an effective treatment for various
autoimmune and inflammatory diseases because of potent anti-inflammatory effects stemming in part from sialylated IgGs
(sIgG) present at 1–3% in IVIG. We investigated the ability of IVIG to prevent fatal HSE when given 24 h post infection. We
discovered a novel anti-inflammatory pathway mediated by low-dose IVIG that protected 129S6 mice from fatal HSE by
modulating CNS inflammation independently of HSV specific antibodies or sIgG. IVIG suppressed CNS infiltration by
pathogenic CD11b
+ Ly6C
high monocytes and inhibited their spontaneous degranulation in vitro.F c cRIIb expression was
required for IVIG mediated suppression of CNS infiltration by CD45
+ Ly6C
low monocytes but not for inhibiting development
of Ly6C
high monocytes. IVIG increased accumulation of T cells in the CNS, and the non-sIgG fraction induced a dramatic
expansion of FoxP3
+ CD4
+ T regulatory cells (Tregs) and FoxP3
2 ICOS
+ CD4
+ T cells in peripheral lymphoid organs. Tregs
purified from HSV infected IVIG treated, but not control, mice protected adoptively transferred mice from fatal HSE. IL-10,
produced by the ICOS
+ CD4
+ T cells that accumulated in the CNS of IVIG treated, but not control mice, was essential for
induction of protective anti-inflammatory responses. Our results significantly enhance understanding of IVIG’s anti-
inflammatory and immunomodulatory capabilities by revealing a novel sIgG independent anti-inflammatory pathway
responsible for induction of regulatory T cells that secrete the immunosuppressive cytokine IL-10 and further reveal the
therapeutic potential of IVIG for treating viral induced inflammatory diseases.
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Introduction
Herpes simplex virus (HSV) is the leading cause of sporadic
encephalitis, which, although rare, can be fatal or result in severe
neurological deficits in survivors [1]. We reported previously that
dysregulated CNS inflammatory responses cause fatal HSE in
129S6 (129) mice. Most importantly, we showed that once CNS
inflammation was initiated by HSV entry into the brainstem,
inhibiting virus replication could not prevent development of fatal
HSE [2,3]. Similar conclusions have emerged from studies with
susceptible BALB/c mice [4].
IVIG comprises human polyclonal IgG derived from pooled
plasma collected from thousands of healthy donors. Initially it was
used to provide normal levels of circulating IgG as replacement
therapy for primary and secondary immunodeficiencies [5,6].
IVIG has a broad repertoire of neutralizing antibodies for various
pathogens and neutralization is commonly assumed to be the
mechanism of protection in secondary immunodeficiencies [7].
Remarkably, early reports that IVIG was able to prevent fatal
HSE in BALB/c mice independently of neutralizing activity, even
when administered up to 48 h post infection (pi), were not further
investigated to elucidate the mechanism(s) of protection [8,9].
IVIG is a FDA approved treatment for immune thrombocyto-
penia (ITP) and Kawasaki’s vasculitis, and dramatic response rates
that exceed 80% have been observed for ITP. The use of IVIG for
treating a variety of autoimmune and systemic inflammatory
diseases has steadily increased to include not only antibody
mediated diseases, but also disorders caused by dysregulated
cellular immunity, such as multiple sclerosis (MS), myasthenia
gravis and graft versus host disease [10,11]. IVIG has been
reported to prevent development of experimental autoimmune
encephalitis (EAE), an animal model of MS, by increasing both the
frequency and suppressive activity of CD4
+ T regulatory cells
(Tregs) [12,13]. Nonetheless, despite intense study, IVIG’s
mechanism(s) of action remain enigmatic, as discussed in several
recent reviews [11,14,15,16,17,18].
Based on studies in mouse models of ITP, serum induced
arthritis and nephrotoxic nephritis, Ravetch and colleagues
proposed a model to explain the sustained anti-inflammatory
effects of IVIG. They proposed that IVIG interacted initially with
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macrophage. The ensuing upregulation of the inhibitory FccRIIb
concomitant with down regulation of the activating FccRIV has
the net effect of raising the activation threshold of effector
monocytes, thereby diminishing inflammation [16,19]. An impor-
tant recent finding by this group was that a subset of IgG
molecules sialylated on Asp297 in the Fc domain could
recapitulate the protective effects of IVIG in the ITP, nephrotoxic
nephritis and arthritis models [20]. Sialylated IgGs (sIgG), which
comprise 1–5% of IVIG, were effective at ,10 fold lower
concentration, which explains the requirement for high dose (1–
2 g/kg) IVIG [16,21].
We report here that low dose (150 mg/kg) IVIG protected all
129 mice from fatal HSE. IVIG mediated protection against
HSE depended on its immunomodulatory activity but was
independent of HSV specific antibodies. We confirmed the anti-
inflammatory activity of purified sIgG, which is accessed with
high dose IVIG. Importantly, we showed that the non-sIgG
fraction of IVIG, corresponding to low dose IVIG, mediated
equally potent anti-inflammatory effects to prevent fatal HSE.
IVIG devoid of sIgG induced a dramatic expansion of Tregs and
ICOS
+ CD4
+ T cells. Protection against fatal HSE was critically
dependent on IL-10 produced primarily by the ICOS
+ CD4
+ T
cells that accumulated in the CNS of IVIG treated but not PBS
treated control mice. Although, signaling via the inhibitory
FccRIIb contributed to IVIG induced suppression of CNS
infiltration, the absence of FccRIIb did not abrogate protection
against fatal HSE, which is characterized by accumulation of
pathogenic Ly6C
high macrophages.
Results
A Single Dose of IVIG Is Sufficient to Protect 129 mice
We investigated IVIG protection in a mouse model of HSE
characterized by massive accumulation of macrophages and
neutrophils in inflammatory lesions in the brainstem (BS) [3]
using a dose of 3.75 mg IVIG/mouse, which was previously
reported to protect all HSV infected BALB/c mice [9]. HSV
inoculated 129 mice were injected i.p. with 3.75 mg IVIG 24 h pi
and survival was compared to PBS treated control mice. While
.90% of the control mice succumbed to HSE by 7–12 pi, all
IVIG recipients survived (Figure 1A). Protection against fatal
HSE depended on the timing of IVIG administration [9].
Although, IVIG prolonged survival of infected 129 mice when
given at 72 or 96 h pi, it nonetheless failed to prevent mortality
(Figure S1). Because IVIG preparations typically contain ,1%
aggregates and 3–15% IgG-dimers [22,23] we evaluated the
contribution of IgG-dimers and monomers to protection. When
HPLC purified IVIG fractions were injected into mice 24 h pi, the
monomeric, but not the dimeric, IgG fraction protected all mice
from fatal HSE (Figure 1A). Hence, IVIG protection resides
exclusively within the monomeric IgG fraction.
HSV Neutralizing Activity Is Dispensable for IVIG
Protection
Purified F(ab)2 and Fc fragments were injected into infected
mice 24 h pi and the mice were monitored for survival. Neither the
F(ab)2 or Fc fragment preparations were protective when given at
4 mg/mouse. However, increasing the Fc fragment dose to
25 mg/mouse (equivalent to high dose IVIG), protected ,65%
of mice (Figure 1B). IVIG is rich in neutralizing antibodies
specific for HSV-1 and 2 [24], and that the F(ab)2 fragments
retained neutralizing activity yet failed to protect suggested that
neutralization was dispensable for IVIG mediated protection [8].
To demonstrate conclusively that IVIG protection against HSE
was independent of HSV neutralizing activity, infected mice were
given IVIG devoid of neutralizing antibodies 24 h pi. As expected,
IVIG adsorbed free of neutralizing, but not non-neutralizing
antibodies, was still able to protect against fatal HSE (Figure 1B
and Table 1). To determine a role for non-neutralizing
antibodies, pooled sera collected from donors seronegative for
both HSV-1 and HSV-2 was administered to infected mice 24 h
pi. Although, the absence of HSV specific antibodies in
seronegative IVIG reduced protection only slightly relative to
IVIG, the effect was statistically significant (Figure 1B, 70%
versus 100%, p=0.014), which suggests that non-neutralizing
HSV specific antibodies present in the HSV adsorbed sera have a
minor role in protection.
Definition of the Protective Component(s) in IVIG
HSV infected mice were given deglycosylated IVIG or IVIG
desialylated at either a2,3 or both the a2,3 and a2,6 linkages 24 h
pi to determine the contribution of glycosylation, and more
specifically sialylation, of IgG to protection in the HSE model.
Deglycosylated IVIG failed to protect, consistent with glycosyla-
tion being mandatory for maintaining the functional integrity of
the Fc domain, which is critical for protection by IVIG [25]. In
contrast to the ITP and arthritis models, $80% of HSV infected
mice treated with 3.75 mg IVIG desialylated with either a2,3 or
a2,6 specific neuraminidases survived (Figure 1C), despite
complete desialylation (Figure S2). To determine if sIgG (S
+
IgG) could prevent HSE induced mortality, mice were given sIgG
purified on Sambucus nigra (SNA) lectin affinity columns. Notably,
.75% of infected mice given 1 mg sIgG purified from IVIG
(HSV
+S
+ IgG) survived compared to ,45% of mice given sIgG
purified from pooled seronegative sera (HSV
2S
+ IgG)
(Figure 1D). Protection declined with lower doses and a sIgG
dose ,0.5 mg failed to protect. Thus, sIgG can protect against
fatal HSE when given at doses corresponding to high dose IVIG,
much greater than that present in 3.75 mg IVIG. The non-sIgG
(S
2) fraction of IVIG also conferred statistically greater protection
Author Summary
We show that fatal HSV encephalitis (HSE) is caused by
excessive brainstem inflammation. Once brainstem inflam-
mation is initiated, antiviral drugs that inhibit only viral
replication are ineffective in protecting against fatal HSE.
Infusion of high doses of pooled human IgG (IVIG) is an
effective anti-inflammatory treatment for various autoim-
mune diseases. One anti-inflammatory mechanism de-
pends on sialylated IgGs (sIgG) present in limiting amounts
(1–3%) in IVIG, hence the need for high doses of IVIG. We
discovered a novel anti-inflammatory pathway mediated
by low doses of IVIG independent of sIgG that prevented
fatal HSE by suppressing CNS inflammation. The non-sIgG
fraction of IVIG induced regulatory CD4
+ T cells that
produced the immunosuppressive cytokine IL-10 in the
brainstem. Importantly, we show that IL-10 is critical for
suppressing the generation of pathogenic inflammatory
macrophages. Thus, IVIG has a remarkable ability to
balance the host inflammatory responses to virus infection
and thereby promotes virus clearance without bystander
damage to the CNS, accounting for survival of all infected
mice. Overall, our results provide important new insights in
understanding IVIG’s anti-inflammatory activity and further
reveal its potential for use in treatment of viral inflamma-
tory diseases.
Non-Sialylated IVIG Induces IL-10 to Suppress Encephalitis
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tered at 3.75 mg/mouse; .90% and ,60% of mice survived,
respectively (Figure 1D). Cumulatively, these results reveal a
novel potent sIgG independent anti-inflammatory pathway
mediated by low dose IVIG.
IVIG Diminishes CNS Inflammation and Prolongs Integrity
of the Blood Brain Barrier
Massive CNS inflammation is the primary cause of fatal HSE in
129 mice, while C57B6 mice, which exhibit minimal CNS
inflammation, are resistant to HSE [3]. Flow cytometric analysis
of leukocyte CD45
high infiltrates in the BS revealed that 129 mice
had 75% CD45
high infiltrates compared to 30% CD45
high
infiltrates for B6 mice at d12 pi (Figure 2A). Although 129 mice
cleared infectious virus from the BS and trigeminal ganglia (not
shown) by d10 pi, they nonetheless failed to control CNS
inflammation (Figure 2B). Compared to control infected 129
mice, IVIG treated mice exhibited a dramatic reduction of
infiltrating CD45
high peripheral leukocytes at d6, 8 and 12 pi
(Figure 2C–F). At d6 pi, CD45
high infiltrates comprised ,12%
(range 6–18%) of total cells recovered from the BS of IVIG treated
129 mice compared to ,30% (range 22–42%) in control 129 mice
(Figure 2C, E). By d8 pi, CD45
high infiltrates comprised more
than 55% (range 45–62%) of total BS cells in control mice
compared to ,24% (range 20–28%) in IVIG treated mice
(Figure 2C, E). The majority of cells that infiltrated the BS of
control 129 mice were CD11b
+ macrophages and neutrophils
(Figure 2E). The few surviving control mice exhibited even more
pronounced inflammation (,75%) at d12 pi (Figure 2A, C)
compared to protected IVIG treated mice (,30%, Figure 2C).
When presented as total cell numbers the striking difference in
leukocyte infiltration is even more dramatic, with an initial 3-fold
Figure 1. Protection against fatal HSE by IVIG and derivatives.
HSV infected 129 mice were injected i.p. at 24 h pi with (A) PBS,
3.75 mg of IVIG, or monomeric or dimeric fractions of IVIG; (B) 3.75 mg
of pooled HSV positive or negative sera, HSV adsorbed IVIG, 4 mg of
F(ab)2, or 4 or 25 mg of Fc fragments; (C) 3.75 mg of IVIG, a2,3- or a2,6-
desialylated IVIG or deglycosylated IVIG or PBS; (D) 1 mg of sialylated
(S
+) or 3.75 mg of non-sialylated (S
2) IgG isolated from IVIG (HSV
+)o r
HSV seronegative (HSV
2) pooled sera and monitored for survival. Data
are representative of 3–5 experiments (n=16–50). **P,0.01 for 1B:
HSV
+ IVIG vs. HSV
2 IVIG; *P,0.05 for 1D: HSV
+S
2 vs. HSV
2S
2 IgG;
***P,0.0001 for 1A: PBS and dimeric IgG vs. IVIG and monomeric IgG,
1B: 4 mg F(ab)2 or Fc fragments vs. IVIG or HSV adsorbed IVIG and 1C:
IVIG vs. deglycosylated IVIG.
doi:10.1371/journal.ppat.1002071.g001
Table 1. Specificities of IVIG derivatives.
IVIG & Derivatives
HSV ELISA
titer
Neutralizing
Titer
Sialylation
Titer
IVIG or Human Serum 1/10240 1/320 + (1/625)
HSV Adsorbed IVIG 1/5120 ,1/2 + (1/625)
*DG – IVIG 1/5120 1/320 2 (,1/5)
+a2,3 DS IVIG 1/5120 1/160 2 (,1/5)
+a2,6 DS IVIG 1/5120 1/320 2 (,1/5)
*HSV
+ S
+ IgG 1/5120 ,1/2 +++
*HSV
+ S
2 IgG 1/5120 1/320 NA
HSV
2 Pooled Sera ,1/5 ,1/2 + (1/1250)
qHSV
2 S
+ IgG ,1/5 ,1/2 +++
qHSV
2 S
2 IgG ,1/5 ,1/2 NA
*DG-IVIG, PNGase F digested IVIG to achieve deglycosylation.
+DS-IVIG, Neuraminidase treated IVIG to remove terminal sialic acid residues at
a2,3- or a2,6- position.
*
/qS
+/2 IgG, SNA lectin column eluted IgG to separate sialylated (S
+)o rn o n -
sialylated (S
2) from either IVIG or HSV negative sera.
NA, not applicable.
doi:10.1371/journal.ppat.1002071.t001
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high cells at d6 pi (5.562.6610
4 in IVIG
treated mice compared to 1.660.5610
5 in controls) that escalated
to a massive 7-fold difference by d8 pi (160.2610
5 in IVIG vs.
7.261.1610
5 in controls; Figure 2C). The reduced CNS
inflammation in IVIG treated 129 mice mirrored the leukocyte
CNS infiltration observed in untreated resistant B6 mice that
survive (Figure 2A, C–F). It is also evident that IVIG’s anti-
inflammatory effects persist long-term (Figure 2C).
Leukocytes infiltrated the brain (Figure 2D, F) and spinal cord
(Figure S3) of control mice robustly by d6 pi, and by d8 pi there
was a 10-fold increase in infiltrates within the brains of control
mice (3.862610
5 at d6 to 3.762.3610
6 at d8) compared to only a
marginal increase in total CD45
high infiltrates in IVIG treated
mice (2.561610
5 at d6 to 4.562610
5 total infiltrates at d8). Thus,
IVIG regulates inflammation by diminishing the infiltration of
cells into the CNS of infected mice. Impaired anti-inflammatory
activity was responsible for the failure of deglycosylated IVIG to
protect 129 mice (Figure 1C), as mice treated with 3.75 mg
deglycosylated IVIG or Fc fragments had increased levels of
CD45
high infiltrating cells, similar to control infected 129 mice
(Figure 2G). We infer that the anti-inflammatory activity of
sialylated Fc fragments accounted for survival of mice treated with
25 mg Fc fragments. Mice that were protected by treatment with
desialylated IVIG, 3.75 mg of S
2 IgG or 1 mg S
+ IgG isolated
from either IVIG or HSV seronegative IVIG also had reduced
levels of CD45
high infiltrating cells, similar to IVIG treated mice
(Figure 2G).
Vigorous inflammation in the CNS of 129 mice suggested the
integrity of the blood brain barrier (BBB) might be severely
compromised in infected control 129 mice but not in the IVIG
recipients. Sodium fluorescein uptake assays performed to assess
BBB integrity showed a .6-fold increase in uptake from d0 to 6 pi
in BS of control mice in contrast to only a ,2.5-fold increase for
IVIG treated 129 mice (Figure 2H and 2C–D), consistent with
the dramatic reduction in CNS inflammation in IVIG treated
compared to control 129 mice. Notably, IVIG was excluded from
the CNS, at least in the first 72 h post infusion, as determined by
micro-PET imaging and biodistribution of Cu
64-labeled IgG
(Figure S4); hence, IVIG acted peripherally to modulate CNS
inflammation.
IVIG Alters the Composition of Leukocytes Infiltrating the
CNS
At both d6 and 8 pi, .70% of the CD45
high leukocytes
infiltrating the BS and brain of infected control 129 mice were Gr-
1
+ (Table 2 and Figure 3A). IVIG treatment of infected mice
dramatically reduced infiltration of this population to ,40% of
total CD45
high cells at d8 pi, equivalent to a ,20-fold reduction in
total Gr-1
+ cells (Figure 3A, Table 2). Gr-1
+ cells are comprised
primarily of Ly6G
+ CD11b
+ neutrophils and Ly6C
high/int F480
+
macrophages. Further analysis of the Gr-1
+ cells in BS of IVIG
treated mice revealed that although IVIG treatment reduced total
numbers of Ly6G
+ F480
2 SSC
high neutrophils within this
population (Table 2), the most dramatic decline was observed
within the Ly6C
high inflammatory macrophage subset
(Figure 3B). Ly6C
high F480
+ SSC
low macrophages, which
comprised 50–60% of total CD45
high cells in both BS and brains
of control mice, were reduced to ,15–17% in the IVIG treated
group (Figure 3B). Total percentages of F480
+ macrophages were
reduced from 66% in BS and 57% in brains of control mice to
28% and 30% in BS and brains, respectively, of IVIG treated
mice, which constituted a 15-fold drop in total macrophage
numbers in the CNS at d8 pi (Figure 3B and Table 2). The
majority of Ly6C
high macrophages isolated from BS of control
mice expressed high levels of FceR1 as compared to markedly
diminished expression on the Gr-1
+ subset present in the BS of
IVIG treated mice (Figure 3C). Thus, these data show early
involvement of inflammatory Ly6C
high macrophages in the disease
process of HSE, confirming earlier results, which showed that anti-
Gr-1 mAb mediated depletion of macrophages and neutrophils
Figure 2. IVIG inhibits CNS inflammation in HSV infected mice. (A) Macrophages infiltrating the brainstem (BS) of infected B6 and 129 mice
at d 12 pi. (B) CD45
high infiltrates (y-axis, left) and HSV titers (y-axis, right) in BS of 129 mice. Cells isolated from (C) BS or (D) brain of PBS or IVIG
treated 129 and B6 mice were analyzed for CD45
high infiltrates at indicated times pi; left y-axis: % CD45
high infiltrates in BS shown as symbols; right y-
axis: total number of CD45
high infiltrating cells as vertical bars. Data representative of 3 experiments (4 mice/time point). Error bars depict standard
errors of mean. Representative FACS plots of (E) BS and (F) brain from IVIG- (left column) and PBS (right column) treated (right column) 129 mice. (G)
Percentage of CD45
high infiltrates in BS of 129 mice treated with derivatives of IVIG or HSV seronegative sera at d6 pi. (H) Assessment of BBB
permeability by sodium fluorescein uptake in infected 129 mice given PBS or IVIG.
doi:10.1371/journal.ppat.1002071.g002
Table 2. IVIG reduces and alters infiltrating cell composition.
Cell subsets: BS of 129 mice PBS: d6 pi IVIG: d6 pi PBS: d8 pi IVIG: d8 pi
Total # in BS (x10
4)
a 71
a 47 133 62
CD45
high infiltrates (% BS)
b 26
b 13 60 26
Gr-1 reactive cells
c 78
c 65 70 40
CD45
high CD11b
+ F480
+ Macs (MHC II
+)
d 55 (62%)
d 40 (70%)
d 65 (90%)
d 30 (100%)
d
Ly6G
+ Neutrophils
c 20 5 15 5
CD11c
+ (CD11b
+) cells
c 30 12 18 15
T cells
c 10 40 20 55
CD45
int microglia (MHC II
+)
d 18 (65%)
d 15 (65%) 15 (65%) 20 (72%)
aTotal numbers in BS represented as cells present in BS of indicated groups.
bCD45
high infiltrates are shown as percentage within BS mononuclear cells.
cAll individual subsets are represented as percentages within CD45
high infiltrating cells.
dNumbers in parenthesis represent % MHC II
+ cells within macrophage or microglial subsets.
doi:10.1371/journal.ppat.1002071.t002
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numbers of Ly6C
high macrophages, IVIG treatment altered the
composition of BS infiltrating cells: IVIG treatment reduced
infiltration of macrophages and neutrophils that predominated the
CNS of control 129 mice while it increased T cell infiltration.
Whereas only 10% and 20% of brain and BS infiltrates were
composed of T cells in control mice, T cells comprised 40% and
55% of the brain and BS infiltrates of IVIG treated mice,
respectively (Table 2). These results emphasize IVIG’s capacity to
regulate not only the generation of pathogenic macrophages, but
Figure 3. IVIG alters the phenotype of macrophages and microglia. CD45
high infiltrates in brain and BS of control or IVIG treated 129 mice at
d8 pi analyzed for (A) Gr-1
+ cells; (B) Ly6C
high and (C) FceR1
+ F480
+ macrophages. (D) MHC II expression on CD45
high macrophages and CD45
int
microglia isolated from BS or brains; frequencies and mean fluorescence intensity (MFI) of MHC II
+ CD45 microglia (boxed regions) shown. (E) MHC I
expression by CD45
int microglia. Data representative of 2–3 experiments (n=6–12 mice).
doi:10.1371/journal.ppat.1002071.g003
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CNS of HSV infected mice.
IVIG Modulates Activation of Macrophages and Microglia
in the CNS
We analyzed MHC class I and II expression on microglia and
macrophages by flow cytometry to determine their activation
status. Although microglia in both control and IVIG treated mice
expressed MHC class I at d6 pi, MHC class II expression was very
low (mean fluorescence intensity [MFI] =0, Table 2). However,
by d8 pi, MHC class II expression on microglia was greatly
increased in the brain of control mice compared to IVIG treated
mice (74% vs. 45%) (Figure 3D), and MHC class I expression
also increased in brains and BS of both groups of mice
(Figure 3E). Surprisingly, both the fraction of microglia that
expressed MHC class II and the MFI were increased in the BS of
IVIG treated mice as compared to control mice (74% vs. 60%,
MFI 150 vs. 57; Figure 3D). Thus, IVIG treatment enhances the
activation state of macrophages and microglia in the CNS, as
demonstrated by MHC I/II (Table 2, Figure 3). Induction of
MHC II expression on microglia in the CNS requires the presence
of IFN-c which is likely derived from T cells infiltrating the BS of
IVIG treated mice (Table 2).
IVIG Modulates Macrophage Degranulation
To determine if macrophages in peripheral lymphoid tissues
have a different activation or degranulation profile, splenocytes
obtained from control and IVIG treated HSV infected mice at d6
pi were stimulated ex vivo for 4 h with or without heat killed HSV
(HK-HSV) antigen in the presence of antibodies to CD107a/b
(LAMP-1 and 2). The majority of splenic macrophages isolated
from control infected mice degranulated spontaneously and
expressed high levels of surface CD107a, even in the absence of
HK-HSV stimulation (Figure 4A), whereas, strikingly, those
isolated from IVIG treated mice did not (Figure 4A). To identify
the highly activated cell subset(s) in spleens of infected 129 mice
with this phenotype, cells were phenotypically distinguished by
surface expression of Gr-1, F480 and Ly6C. Both the Gr-1
+
CD11b
+ F480
2 SSC
high neutrophils and the mature non-
inflammatory macrophages (Ly6C
2 F480
+) degranulated only in
response to stimulation with HK-HSV antigen, whereas the
Ly6C
high inflammatory macrophages expressed high levels of
CD107a without stimulation (Figure 4B). Similarly, there were
more spontaneously degranulating CD45
high CD11b
+ macrophag-
es in the brain (32% vs. 16%) and BS (74% vs. 51%) of control
mice compared to IVIG treated mice (Figure 4C). Moreover, as
macrophages were more prevalent in infected BS of control PBS
treated mice than in IVIG treated mice, the total numbers of
degranulating macrophages were greatly increased (Table 2 and
Figure 3). Thus, macrophages in the CNS and lymphoid organs
of IVIG recipients are anti-inflammatory, while those in control
mice have a pathogenic phenotype.
IVIG Alters FcR Expression on Macrophages and
Monocytes
Modulation of FcR expression is one of many mechanisms
proposed to explain IVIG’s anti-inflammatory activity [27,28].
Therefore, we examined FcR expression on monocytes from
lymphoid organs of control and IVIG treated mice. Surface
Ly6C
high expression facilitated discrimination of inflammatory
from non-inflammatory CD11b
+ F480
+ macrophages (Figure 5A).
Splenic Ly6C
2 macrophages (Figure 5A) in control and IVIG
treated mice expressed similar levels of the inhibitory FccRIIb and
activating FccRIII receptors, as determined by CD16/32
reactivity. In contrast, the Ly6C
high inflammatory subset, which
was more prevalent in the spleens of control mice, expressed much
lower levels of FccRIIb/III compared to those in the spleens of
IVIG treated mice. FccRI expression on both subsets was similar
in both groups (Figure 5A). To determine a role for FccRIIb/III
receptors in IVIG’s anti-inflammatory effects, CNS inflammation
was analyzed at d8 pi in IVIG treated infected mice that were also
treated with the 2.4G2 blocking mAb that inhibits FccRIIb/III
signaling [29]. Flow cytometry analysis revealed that the absence
of FccRIIb/III signaling compromised IVIG’s ability to suppress
CNS infiltration. With intact FccRIIb/III signaling, there were
,20–25% CD45
high infiltrating cells in the CNS of IVIG treated
mice (Figure 2C and E). However, inhibition of FccRIIb/III
signaling resulted in increased CNS infiltration with ,70%
CD45
high cells present in the BS of these mice (Figure 5B).
Interestingly, in wild-type (WT) mice, IVIG reduced macrophage
influx while it increased infiltration of T cells (Table 2), whereas
in the absence of FccR signaling, CD11b
+ F480
2 monocytes
dominated BS infiltrates (Figure 5B). The majority of monocytes,
however, expressed intermediate levels of Ly6C and low levels of
MHC II (Figure 5B), indicating that they were not inflammatory.
Thus, FccR signaling is required for IVIG mediated suppression
of CNS infiltration, but not for modulation of pathogenic
inflammatory macrophages.
To determine whether the inhibitory FccRIIb receptor or the
activating FccRIII receptor was critical for suppression of
inflammation, we compared CNS inflammation in infected IVIG
treated BALB/c FccRIIb knock-out (KO) mice at d6 pi to that in
IVIG treated BALB/c mice and IVIG treated BALB/c mice given
anti-FccRIIb/III antibodies. IVIG suppressed CNS leukocyte
infiltration in BALB/c mice as effectively as in 129 mice, but it
failed to suppress CNS infiltration in either FccRIIb/III depleted
or FccRIIb KO mice at d6 and 8pi (Table 3). Similar to results
seen with 129 mice, the absence of FccRII/III signaling skewed
CNS infiltrates to predominantly CD11b
+ monocytes rather than
T cells (Table 2 and Figure 5C), but, very few of these
monocytes were Ly6C
high, indicating they were not inflammatory
(Figure 5C). The results shown in Table 3 indicate that signaling
via FccRIIb rather than FccRIII contributed to IVIG mediated
modulation of CNS infiltration and modulation of the composition
of cellular infiltrates. Surprisingly, despite unmitigated CNS
leukocyte infiltration in IVIG treated 129 and BALB/c mice
deficient in FccRIIb signaling, all mice survived and showed no
symptoms of encephalitis.
IVIG Induces Regulatory CD4
+ T Cells that Control Hyper-
Inflammatory Responses
T cells were predominant in CNS infiltrates of IVIG treated
mice at d8 pi. IVIG expanded CD4
+ Tregs that contributed to
protection in two different models of pathogenic inflammation
[12,30]. We used 129 FoxP3-GFP reporter mice to investigate the
possibility that IVIG induced Tregs in the HSE model. Analysis of
HSV infected, IVIG treated 129 FoxP3-GFP reporter mice
revealed that the majority of the CD4
+ T cells in the spleen were
FoxP3
+ CD25
+ Tregs at d8 (,40%) and d18 pi (,30%,
Figure 6A). In contrast, the percentage of Tregs was only
modestly increased in the spleens of infected PBS treated control
mice (,15%, Figure 6A) and these Tregs were obviously
ineffective in suppressing the exaggerated CNS inflammatory
responses. To determine whether the S
+ or S
2 IgG component of
IVIG induced Tregs, we analyzed 129 FoxP3-GFP reporter mice
treated separately with the two preparations at d6 pi (Figure 6B).
S
2 IgG dramatically expanded Tregs in the cervical lymph nodes
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+ IgG did not induce Tregs
(3% in CLN and 12% in spleen). Interestingly, FoxP3
+ CD4
+
Tregs were not present in the infected BS of either IVIG treated or
control mice, suggesting the Tregs function primarily in lymphoid
organs (Figure 6C). We used adoptive transfer of IVIG induced
or control Tregs from infected or naı ¨ve mice to assess the
contribution of Tregs to IVIG’s anti-inflammatory effects, which
facilitated assessing their intrinsic suppressive potential. FoxP3
+
GFP
+ Tregs isolated from the spleens of naı ¨ve, IVIG and PBS
treated HSV infected FoxP3-GFP mice on d8 pi were adoptively
transferred into naive 129 recipients that were challenged 24 h
later with HSV. Most recipients of Tregs isolated from IVIG
treated HSV infected FoxP3-GFP mice, but not control PBS
treated or naı ¨ve mice, were protected long-term (Figure 6D).
This result shows that adoptively transferred IVIG induced Tregs
prevented lethal HSE while Tregs from the PBS treated control or
naı ¨ve mice were non-functional. We investigated the requirement
for Tregs in protection afforded by IVIG by using anti-CD25
antibodies to deplete Tregs prior to HSV infection and during
subsequent IVIG treatment. Unexpectedly, all Treg depleted mice
survived HSV challenge, which indicated that Tregs were not
essential for IVIG induced suppression of pathogenic CNS
inflammatory responses (Figure 6D).
To determine if, in addition to Tregs, another T cell subset was
involved in IVIG’s anti-inflammatory effects, we analyzed spleen
and CLN CD4
+ T cells for expression of cell surface markers such
as ICOS, GARP, CD103 and GITR that are characteristic of
regulatory T cells. Only ICOS was dramatically up regulated on
CD4
+ T cells isolated from both CLNs and spleens of IVIG
treated mice compared to control mice (Figure 6E). Upregulation
of ICOS expression occurred preferentially within the activated
CD62L
low population (spleen—IVIG: 62% vs. control: 43%;
CLN—IVIG: 78% vs. control: 12%). Importantly, only ,20–26%
of the ICOS
+ CD62L
low CD4
+ T cells in the spleens of both
groups of mice were FoxP3
+ Tregs. Similarly, the majority of
activated ICOS
+ CD4
+ T cells in the CLN of IVIG treated mice
did not express FoxP3, indicating that they were not Tregs, while
about 46% of the corresponding activated CD62L
low ICOS
+
CD4
+ T cells in control mice were FoxP3
+ Tregs. Importantly,
ICOS
+ FoxP3
2 CD4
+ T cells were the major constituents of the
CD4
+ T cell population in the BS of IVIG treated mice but not of
control mice at d6 pi (Figure 6F). Moreover, both CD11c
+ DC
and F480
+ macrophages isolated from the BS of IVIG treated 129
mice at d6 pi expressed higher levels of ICOS-L, the ligand for
ICOS, compared to those from control 129 mice (Figure 6G).
These data show that IVIG elicits different populations of
regulatory CD4
+ T cells, and that whereas Tregs act primarily
in peripheral lymphoid organs, ICOS
+ CD4
+ T cells may function
both in the periphery and at sites of inflammation in the BS.
IL-10 Is Critical for IVIG’s Anti-Inflammatory Effects
To determine the mechanism(s) by which regulatory CD4
+ T
cells suppress inflammatory CNS responses, we used the
RT
2Profiler PCR array kit (SABiosciences, Frederick, MD) to
compare the expression profiles of inflammatory genes in the BS of
control and IVIG treated mice at d6 pi to those of uninfected
Figure 4. IVIG inhibits macrophage degranulation. (A) CD107a
expression by splenocytes isolated at d6 pi from IVIG- (left plot) or PBS-
treated (right plot) 129 mice. (B) Spleen cells isolated from PBS treated
infected mice at d6 pi were delineated into three subsets based on
CD11b and Gr-1 reactivity (top left plot). Gr-1
high CD11b
+ neutrophils
(top right), Gr-1
+ CD11b
+ inflammatory monocytes (bottom left) and Gr-
1
2 CD11b
+ macrophages (bottom right) were analyzed for CD107a
expression with (black lines) or without (blue line) incubation with heat-
killed HSV. Isotype controls (red, without; green, with HK-HSV
stimulation) are included. (C) Cells from brain (top) and BS (bottom)
of PBS (left) and IVIG treated (right) 129 mice at d8 pi were analyzed for
CD107a/b expression in the absence of antigen stimulation. Data
representative of 2 experiments (n=6–8 mice).
doi:10.1371/journal.ppat.1002071.g004
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+ (top right 2 plots) and Ly6C
2 (bottom right 2 plots) subsets of CD11b
+ splenic macrophages
in control PBS (top left) and IVIG treated (bottom left) 129 mice at d 6 pi analyzed for FccRI (middle plot) or FccRIIb/III (right plot) expression. (blue
lines: PBS treated macrophages; red lines: IVIG treated macrophages). (B) CD45
high CD11b
+ monocytes in BS of anti-FccRIIb/III mAb depleted IVIG
treated 129 mice at d8 pi (left). F480
+ macrophages analyzed for MHC II
+ (middle) and Ly6C expression (right); plots gated for CD45
high infiltrates. (C)
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in BS of IVIG treated mice compared to uninfected mice, but not
significantly compared to control PBS treated infected mice
(Figure 7A). In contrast, relative to control uninfected mice, the
BS of IVIG treated infected mice showed an ,80-fold increase in
IL-10 mRNA expression compared to only an 18-fold increase in
BS of control PBS treated mice. Concordant with the RT-PCR
results, intracellular flow cytometric analysis following stimulation
with PMA and ionomycin revealed significantly increased IFN-c
and IL-10 expression by CD45
high cells, specifically the CD4
+ T
cells isolated from the BS of IVIG treated mice at d6 pi
(Figure 7B, S5). Interestingly, both CD45
int microglia and a
population of CD45
neg cells, possibly astrocytes, in the BS of both
groups of mice secreted IL-10, even without stimulation (Figure
S5). Furthermore, by d14 pi there was an even greater increase in
the percentages of IFN-c and IL-10 secreting CD45
high and CD4
+
T cells in the BS of IVIG treated mice. Importantly, only the
ICOS
+ CD4
+ T cells in both IVIG treated and control PBS
treated mice secreted IL-10 following stimulation (Figure 7C).
ICOS
+ cells dominated the CD4
+ T cell population in the BS of
IVIG treated mice (70%) but not the BS of control mice (23%). IL-
10 secreting cells comprised more than 50% of the ICOS
+ CD4
+
population in the BS of IVIG treated mice compared to ,30% in
the BS of control PBS treated mice (Figure 7C). These results
suggest that ICOS and IL-10 may orchestrate suppression of
hyper-inflammatory immune responses in the CNS of infected
mice.
To determine whether IL-10 was critical for IVIG mediated
protection against HSV induced CNS inflammation, we compared
the outcome of infection in 129 WT and IL-10 KO mice treated
with either IVIG or PBS at 24 h pi. As expected, the majority of
129 WT and IL-10 KO mice treated with PBS succumbed to
HSE. While IVIG protected all 129 WT mice, only ,45% of
IVIG treated IL-10 KO mice survived to d25 pi (Figure 7D) and,
of these mice, some exhibited symptoms of neurological sequelae,
including altered gait, hunched back and weight loss.
Having established a critical role for IL-10 in IVIG protection
against fatal HSE, it was important to show that impaired
protection of IL-10 KO mice by IVIG was due to impaired
suppression of CNS inflammation. Comparison of inflammatory
responses in the BS of infected 129 IL-10 KO and WT mice
treated with IVIG revealed that in the absence of IL-10, CNS
inflammation continued unabated in the IL-10 KO mice
(Figure 7F and 2E). High levels of CD45
high infiltrates (82%)
were present in the BS at d8 pi, the majority of which were
inflammatory Ly6C
high MHC II
+ CD11b
+ F480
+ macrophages
(Figure 7F). Therefore, we concluded that IL-10 is essential for
IVIG to suppress CNS inflammation and inhibit development of
pathogenic Ly6C
high inflammatory macrophages. Interestingly, in
the absence of IL-10, macrophages rather than T cells dominated
immune cell infiltrates in the BS of IVIG treated 129 WT mice
(Figure 3B, 7F and Table 2). Concordant with their
inflammatory phenotype, the majority of macrophages isolated
from the brain and BS of PBS and IVIG treated IL-10 KO mice
degranulated, even in the absence of HK-HSV, confirming their
pathogenic phenotype (Figure 7G). Importantly, macrophages
from IVIG treated IL-10 KO mice degranulated much more than
macrophages isolated from IVIG treated 129 WT mice (62% vs.
16% for brain and 80% vs. 51% for BS, respectively) (Figures 4C
and 7G). This effect was even more exaggerated if the increased
numbers of macrophages in the BS of IL-10 KO mice compared
to WT mice was considered (Figures 3 and 7). To determine if
CD4
+ T cells were compromised in IL-10 KO mice, we compared
expression of ICOS in peripheral lymphoid organs to that in 129
WT mice treated with IVIG. Expression of both CD25 and ICOS
was reduced in the CLN of IL-10 KO mice compared to 129 WT
mice (Figure 7E). Cumulatively, these results suggest that IL-10
secreting CD4
+ ICOS
+ T cells may drive suppression of
inflammation and modulation of inflammatory macrophages.
The potential regulatory role of IVIG induced ICOS
+ CD4
+ T
cells in suppression of macrophage activation and CNS inflam-
mation is currently under investigation.
Discussion
We reported previously that HSE progression was not affected
by Acyclovir inhibition of HSV replication after virus had entered
the BS, which is consistent with immune mediated pathology
rather than virus cytopathology causing death [3]. The number of
clinical reports speculating on a role for immune pathology in
HSE has also been increasing [31], indicating increased interest in
this idea. In our studies of IVIG mediated protection against fatal
HSE, 100% of 129 mice treated with low dose (3.75 mg/mouse)
IVIG 24 h pi were protected from fatal HSE. This dose of IVIG is
much lower than the 1–2 g/kg high dose typically used for
treatment of autoimmune diseases [28,32]. The monomeric IgG
Table 3. FccRIIb is required for control of CNS infiltration.
Cell subsets: in
BALB/c BS
PBS
d6pi
IVIG
d6 pi
aFccRIIb/III
mAb + IVIG d6 pi
FccRIIb KO mice +
IVIG d6 pi
PBS
d8 pi
IVIG
d8 pi
FccRIIb KO mice +
IVIG d8 pi
Total # in BS (x10
4)
a 60
a 30 50 40 170 75 120
CD45
high infiltrates 32
b 20 40 36 76 40 66
CD45
hi CD11b
+ cells
c 70 49 74 89 82 40 60
T cells
c 10 40 17 8 15 55 35
aTotal numbers in BS represented as cells present in BS of indicated groups.
bCD45
high infiltrates are shown as percentage within BS mononuclear cells.
cAll individual subsets are represented as percentages within CD45
high infiltrating cells.
doi:10.1371/journal.ppat.1002071.t003
Infected BALB/c mice given IVIG following treatment with either isotype (left) or anti-FccRIIb/III mAb (middle) and analyzed for CD45
high monocytes
at d6 pi (top row); cells gated on CD45
high infiltrates. Infected FccRIIb KO mice given IVIG and analyzed for infiltrating monocytes (right). CD45
high
CD11b
+ gated monocytes from these groups analyzed for Ly6C and MHC II
+ expression (bottom row). Data representative of 2 experiments (n=6–8
mice).
doi:10.1371/journal.ppat.1002071.g005
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comprised of idiotype-anti-idiotype pairs [23,33] was not. Purified
Fc fragments have been shown to suppress ITP and Kawasaki
disease in humans [18]. In our studies, at low dose (4 mg/mouse),
Fc fragments failed to protect, whereas a high dose of Fc (25 mg/
mouse) conferred significant protection, analogous to results
obtained for ITP, nephrotoxic nephritis and serum transfer
arthritis in experimental mouse models given 25 mg IVIG/mouse
[28,34].
Protection against fatal HSE by IVIG was independent of HSV
specific antibodies and entry into the CNS during early acute
infection. Rather, protection correlated with early and profound
suppression of pathogenic inflammatory responses in the BS of
infected IVIG treated 129 mice, which effectively prolonged the
integrity of the BBB. In addition to markedly reducing CNS
infiltration of CD45
high Ly6C
high inflammatory monocytes, IVIG
treatment profoundly altered the phenotype of these cells. A
particularly impressive manifestation of IVIG’s potent immuno-
modulatory effects was the suppression of spontaneous and antigen
induced degranulation by highly activated Ly6C
high monocyte/
macrophages isolated from spleen, CLN and BS of HSV infected
mice. Thus, IVIG acted peripherally to modulate early innate
responses emanating from both infiltrating and resident immune
cells in the CNS to protect against fatal HSE. We infer that failure
of IVIG to protect when given at later times after infection is likely
due to CNS infiltration by non-modulated aggressive Ly6C
high
inflammatory monocytes prior to IVIG administration.
Ravetch and colleagues have provided extensive data to show
that purified sIgG, which is present at 1–3% in IVIG, afforded
complete protection against ITP and arthritis when given at a 10-
fold lower dose than the usual high dose of 1.0 g/kg, thereby
explaining the need for high dose IVIG in order to access its anti-
inflammatory activity [21,32]. They showed further that specific
removal of a2,6 linked sialic acid residues on Asp297 in the Fc
domain or deglycosylation, which impairs structural integrity of
the Fc domain, both abolished IVIG’s anti-inflammatory activity
in ITP and arthritis models [21,32,35]. We speculated that the
sIgG mechanism applied also to the HSE model. Deglycosylation
of IVIG abrogated protection against fatal HSE, confirming the
critical role of the Fc domain. In contrast, desialylation of IVIG
did not significantly reduce protection against fatal HSE, contrary
to results from the ITP and arthritis models [21,32]. Notably,
when HSV infected mice were given escalating doses of affinity
purified sIgG ranging from 100 ng to 1 mg, robust protection
against fatal HSE (,70% survival) was observed only with doses
.500 ng; drastically reduced survival was observed with doses less
than 500 ng. Similar results were obtained with the purified Fc
fragment. It was obvious from these results that sIgG could not be
responsible for the protective effects of low dose IVIG, as it was
present in too low an amount compared to the amount of purified
sIgG required for robust protection. This important conclusion
predicted that IVIG devoid of sIgG (HSV
+S
2 IgG) would be
protective, and indeed, .90% of infected mice given 3.75 mg of
HSV
+S
2 IgG survived. Furthermore, CNS inflammation in these
mice was reduced to an extent comparable to that seen with IVIG
or sIgG treated mice. Thus, we have identified a sIgG independent
anti-inflammatory pathway mediated by low dose IVIG that is as
potent as IVIG.
HSV
+S
2 IgG conferred statistically greater protection com-
pared to HSV
2S
2 IgG, which is consistent with greater protection
afforded by HSV seropositive compared to seronegative IVIG.
Experimentally, immune complexes (ICs) formed in vitro or in vivo
can mimic the protective effect of IVIG in, for example, ITP and
serum induced arthritis models [16,36,37,38]. Since IC formation
would be expected in infected mice receiving HSV seropositive
compared to seronegative IgG, we are investigating the potential
role of ICs in mediating the anti-inflammatory effects of low dose
IVIG.
Several studies reported an indispensable role for expression of
the inhibitory FccRIIb on effector macrophages and monocytes in
IVIG’s anti-inflammatory effects [39,40,41]. IVIG markedly
upregulated FccRIIb expression on CD11b
+ Ly6C
high inflamma-
tory monocytes in HSV infected mice, while expression of the
activating FccR1 was unaffected. Suppression of CNS infiltration
was abolished by treating 129 and BALB/c mice with the 2.4G2
blocking mAb that targets FccRIIb and FccRIII or by genetic
ablation of FccRIIb signaling in BALB/c mice. Signaling via
FccRIIb in IVIG treated mice biased CNS infiltrates in favor of T
cells rather than the predominant monocyte influx seen in PBS
treated control mice. Remarkably, IVIG was still able to inhibit
development of highly activated Ly6C
high inflammatory mono-
cytes in BALB/c mice deficient in FccRIIb expression, and all
mice survived despite high levels of cells infiltrating the CNS. An
important finding in the HSE model was that following IVIG
treatment, FccRIIb signaling acted primarily to limit CNS
infiltrates and modulate their composition, but was dispensable
for modulation of monocyte activation.
The observation of potent up regulation of IL-10 transcripts in
the BS of IVIG treated infected mice revealed that IVIG induced
functional Tregs. An important new finding was that the non-sIgG
fraction of IVIG was primarily responsible for induction of Tregs.
Regulatory T cell epitopes (Tregitopes) capable of inducing Tregs
were recently identified in the Fc domain of IgG [42]. However,
our results imply that IVIG induces Tregs independently of
presentation of Tregitopes, since purified sIgG was unable to
induce Tregs even though it should contain Tregitopes. IVIG has
been reported to induce Tregs in various models of inflammatory
disease [12,43], which could account for its long-term protective
effects, including in our HSE model. Using EGFP-FoxP3 reporter
mice, we showed that IVIG significantly expanded FoxP3
+ Tregs
and that Tregs purified from infected IVIG treated, but not
control PBS treated, EGFP-FoxP3 mice protected infected 129
Figure 6. IVIG induced Tregs mediate but are not essential for anti-inflammatory effects in the CNS. (A) Representative FACS plots of
CD4
+ Tregs in the spleens of IVIG treated HSV infected 129 mice (top, left plot) expressing FoxP3 (top right). Percentage of FoxP3
+ Tregs in CD4
+
splenocytes of PBS or IVIG treated infected 129 FoxP3-GFP mice at the indicated time points pi (bottom). (B), Percentage of Tregs within CD4
+ T cells
in CLN (left) and spleens (right) at d6 pi in infected 129 FoxP3-GFP mice given either S
2IgG (red dots) or S
+IgG (blue dots). (C) BS CD45
high infiltrates
in IVIG (left) or PBS (right) treated (right) infected 129 FoxP3-GFP mice at d8 pi were analyzed for FoxP3
+ CD3
+ (top) or CD4
+ (bottom) T cells; plots
depict CD45
high gated cells. (D) Infected 129 mice given IVIG were depleted of Tregs using anti-CD25 mAb and monitored for survival (blue squares).
FoxP3
+ CD4
+ Tregs isolated from the spleens of IVIG treated HSV induced (red square), PBS treated HSV induced (green triangles) or naı ¨ve mice
(circles) were transferred into 129 WT mice that were infected with HSV and monitored for survival. (E) Representative FACS plots showing activated
ICOS
6 CD4
+ T cells in spleens (left 2 plots) and CLN (right 2 plots) of PBS (top row) and IVIG (bottom row) treated (bottom row) HSV infected 129
FoxP3-GFP mice at d8 pi. 2
nd and 4
th plots gated on CD62L
low CD4
+ T cells. (F) BS cells in PBS (left) or IVIG treated (right) HSV infected mice at d6 pi
gated on CD45
high CD4
+ T cells analyzed for ICOS expression. (G) BS CD45
high CD11c
+ DCs (left) or F480
+ macrophages (right) in PBS (red lines) or IVIG
treated (blue lines) infected mice at d6 pi probed for ICOSL expression. Data representative of 2 experiments (n=6–8 mice).
doi:10.1371/journal.ppat.1002071.g006
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only expands Tregs, but also augments their effector function.
Unexpectedly, Treg depletion during infection of IVIG treated
mice did not prevent anti-inflammatory responses or reduce
survival. Possible explanations are that IVIG induced redundant
regulatory cell populations, including, for instance, Tr1 regulatory
T cells that secreted high levels of IL-10 [44,45,46]. We observed a
dramatic expansion of ICOS
+ FoxP3
2 CD4
+ T cells in the spleen
and draining CLN of IVIG treated, but not control PBS treated,
infected mice, and these cells also localized to the BS. ICOS is
Figure 7. IL-10 is required for IVIG’s anti-inflammatory effects in the CNS. (A) Quantification of IFN-c, TGF-b and IL-10 mRNA at d6 pi in BS
of infected 129 mice treated with PBS or IVIG. (B) Intracellular IFN-c and IL-10 expression after antigen stimulation of CD45
high (top) or CD4
+ T cells
(bottom) at d6 and d14 pi in the BS of infected 129 mice given either IVIG or PBS. (C) BS CD4
+ T cells in IVIG treated (top) or control (bottom) 129
mice at d6 pi analyzed for ICOS and IL-10 expression with (right) or without (left) PMA + ionomycin; plots gated on CD45
high CD4
+ T cells. (D) HSV
infected 129 WT or IL-10 KO mice were given IVIG or PBS at 24 h pi and monitored for survival. (E) FACS plots gated on CLN derived CD4
+ T cells
showing CD25 and ICOS expression. (F) BS CD45
high infiltrates in IVIG treated HSV infected IL-10 KO mice at d8 pi analyzed for expression of MHC II
and CD11b (top). FACS plots gated on BS CD45
high F480
+ macrophages depicting Ly6C and MHC II expression (bottom). (G) Degranulation of
CD45
high gated cells as measured by CD107a/b expression (blue dots) in the absence of HK-HSV stimulation in the brain (top) and BS (bottom) of PBS
(left) or IVIG (right) treated (right) infected IL-10 KO mice at d 8 pi. Isotype control shown in red. Data representative of 2–4 experiments (n=6–12
mice).
doi:10.1371/journal.ppat.1002071.g007
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expressed on other regulatory cells, such as Tr1 cells [47], hence
we are investigating the potential regulatory role of the ICOS
+
CD4
+ T cells induced by IVIG.
The immunosuppressive cytokine IL-10 was essential for
protection against pathogenic hyper-inflammatory responses in
the CNS, since survival of infected IVIG treated 129 IL-10 KO
mice was drastically reduced. Notably, IVIG failed to suppress
CNS infiltration or spontaneous degranulation by splenic
macrophages from IL-10 KO mice. Highly activated inflamma-
tory Ly6C
high macrophages were predominant in the extensive
CD45
high infiltrates in BS of infected IL-10 KO mice. In contrast,
IVIG treated FccRIIb KO mice survived, despite high levels of
CNS CD45
high infiltrates comparable to those in IL-10 KO mice,
which implicates the Ly6C
high inflammatory macrophages as
being causally involved in the high mortality of IL-10 KO mice.
Thus, these results emphasize that the quality of the inflammatory
response rather than just its magnitude is the critical determinant
of pathogenic outcome.
Significant induction of IL-10 and IFN-c expression by IVIG in
primarily CD4
+ T cells was evident early after treatment in the BS.
Interestingly, ICOS
+ CD4
+ T cells that were predominant
amongst CD4
+ T cells in BS of IVIG treated, but not control,
mice were the major producers of IL-10. HSV infection of
microglia, even though abortive, has been reported to induce
robust expression of proinflammatory cytokines and chemokines.
In vitro, exogenous IL-10 was shown to attenuate this response
[48,49,50]. IL-10 can exert autocrine inhibitory effects on
macrophages and dendritic (DCs) cells that inhibit development
of TH1- and TH2-type responses [51], while IL-10 produced by
TH1, TH2 and TH17 cells represents a feedback loop to regulate
the effector functions of macrophages and DCs [52]. These
important immunoregulatory functions of IL-10 fit well with its
essential role in promoting balanced inflammatory responses in
IVIG treated mice that favor clearance of HSV without bystander
immune pathology. Cumulatively, these results show that IVIG
induced IL-10 producing ICOS
+ CD4
+ T cells are required for
long-term regulation of CNS inflammatory responses.
One model to explain IVIG’s anti-inflammatory activity
proposes that sIgGs present at ,3% in IVIG trigger anti-
inflammatory responses upon binding SIGN-R1 expressed on
sensor marginal zone splenic macrophages in mice [18,20,35].
Results from our studies of IVIG protection against fatal HSE
induced by dysregulated CNS inflammation not only support, but
extend the model by demonstrating existence of a second pathway
induced by the non-sIgG fraction that was highly effective even
with low dose IVIG. Whereas FccRIIb was essential for
prevention of ITP and arthritis by sIgG, it was not important
for protection against fatal HSE by low dose IVIG (i.e., lacking
sIgG). The non-sIgG pathway induced Tregs as well as ICOS
+
CD4
+ T cells that produced IL-10, the latter being essential for the
anti-inflammatory effects of low dose IVIG. However, Kaneko et.
al. reported that desialylated IVIG failed to protect against serum
induced arthritis, as inflammatory infiltration of the joints was not
inhibited [21]. This discrepancy may be due to differences in the
experimental models used. Alternatively, the non-sIgG fraction of
IVIG may function optimally to elicit anti-inflammatory responses
in the context of virus induced inflammatory diseases as opposed
to autoimmune diseases. In sum, our results significantly advance
understanding of IVIG’s anti-inflammatory and immunomodula-
tory activities and reveal the potential utility of IVIG for treating
viral infections in which excessive inflammatory responses
contribute to disease pathology, such as in West Nile virus and
highly pathogenic influenza virus infections.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All animal studies were
conducted under a protocol approved by the Institutional Animal
Care and Use Committee (IACUC, Permit # A3001-01) of City of
Hope to ensure the highest ethical and humane standards were
followed.
Mice and Virus Inoculation
129S6 WT (Taconic, Hudson, NY), 129 FoxP3-GFP [53] and
129 IL-10 KO (Jackson Laboratories, Bar Harbor, Maine) mice
were bred in the vivarium at City of Hope. Male mice of 6–8
weeks of age were infected with HSV 17+ strain. Mice were
sedated with ketamine (60 mg/kg) and xylazine (5 mg/kg) prior to
HSV inoculation by corneal scarification with 3200 PFU
(equivalent to 10 LD50 for the 129 WT strain) as previously
described [3]. Infected mice were monitored daily as previously
described [3].
Administration of Intravenous Immunoglobulin (IVIG)
and Antibodies
Pooled human serum was obtained from Sigma-Aldrich (St.
Louis, MO, USA) and IVIG (Carimmune, NF) was obtained
from CSL Behring (King of Prussia, PA, USA). The recipient
group was intraperitoneally (i.p.) injected with 0.5 ml of either
human sera or IVIG (3.75 mg/mouse, as indicated) 24 h pi.
IVIG and various derivatives were administered 24 h pi unless
otherwise stated. The dose of IVIG was 3.75 mg/mouse, based
on an earlier study [9]. IVIG dose ranging studies demonstrated
that 1.5 mg was the minimal protective dose for HSV infected
129 mice (Figure S1).
For some experiments, HSV antibodies were removed from
IVIG by adsorption with HSV infected monolayers of Vero cells.
Adsorbed antibody was used after confirming the absence of
neutralizing activity [8]. Desialylation and deglycosylation of
IVIG was performed as described previously [32]. Briefly, for
desialylation, IVIG (100 mg) in sodium citrate buffer (0.05 M,
pH 6.0) was incubated (37 C, 40 h) with 700 units of
recombinant a2,3 or a2,3/a2,6 neuraminidase (Clostridium perfin-
gens, New England BioLabs). For deglycosylation, IVIG (100 mg)
in sodium phosphate buffer (0.2 M, pH 8.5) was incubated
(37uC, 48 h) with 25,000 units of PNGaseF (Flavobacterium
meningosepticum, New England BioLabs). Monomer fractions of
deglycosylated or desialylated IVIG preparation (3 mg/mouse)
purified by HPLC were used. For depletion of FoxP3
+ CD4
+
Tregs and FccRIIb/II expressing CD11b
+ cells, mice were
injected with 4 doses of either anti-CD25 mAb PC61 (250 mg) or
anti-FccRIIb/III mAb 2.4G2 (500 mg) on days 22, 0, +1, +2p i .
All mice were inoculated with HSV at day 0 pi and received
either IVIG or PBS i.p. on day +1 pi. Depletion of cell subsets
was confirmed by flow cytometry.
Isolation of Mononuclear Cells from the CNS
CNS derived mononuclear cells were isolated as previously
described [3]. Briefly, brains, BS and spinal cords were removed
separately from mice perfused with PBS, minced and digested with
collagenase and DNAse for 30 min prior to centrifugation (12506
g, 50 min) on a two step Percol gradient [3]. Brain refers to the
whole brain minus the brainstem. The enriched population
contained CNS infiltrating CD45
high cells, CD45
int microglia
and CD45
neg CNS resident glial cells. CD45
high cells comprised ,
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WT mice. Cell viability was greater than 95% as revealed by
trypan blue staining. We confirmed that enzyme digestion did not
affect expression of cell surface markers.
Flow Cytometric Analysis
Single cell suspensions isolated from either, brain, BS, spleen
or CLN were blocked with a 10% Fmixture of normal mouse,
rat and horse serum and rat anti-mouse CD16/32 (2.4G2, BD
PharMingen) for 15 min prior to incubation with antibodies
(Abs) to determine cell surface expression of various markers.
Phycoerythrin (PE), FITC or allophycocyanin conjugated Abs
specific for F480 (BM8), CD11b (M1/70), Gr-1 (RB6-865), CD8
(53-6.7), CD4 (RM4-4), ICOS (7E.17G9), CD62L (MEL-14),
CD25 (PC61.5), IFN-c (XMG1.2), IL-10 (JES5-16E3), FceR1
(MAR-1), MHC class I (28-14-8) and class II (M5/114-15.2)
were obtained from eBioscience (San Diego, CA). FITC, PE or
PerCP conjugated Ly6-G (1A8), Ly6-C (AL-21), CD45 PerCP
(30-F11), CD107a (1D4B) and CD107b (ABL-93) were obtained
from BD PharMingen (San Jose, CA). All isotype controls were
obtained from eBioscience. In the Figure Legends and Results,
all references to infiltrating cells or inflammatory cells from
either BS or brain refer to mononuclear cells isolated from either
compartment distinguished by their CD45
high expression. F480
+
macrophages were characteristically CD45
high, CNS resident
microglia CD45
int and glial cells CD45
neg. Activation of both cell
subsets was determined by their mean fluorescence intensity of
expression of MHC class II molecules. Efficiency of degranula-
tion by macrophages was determined in vitro in the absence of
antigen stimulation or following stimulation of cells for 5 h with
heat-killed HSV in the presence of anti-CD107a/b antibodies to
capture cell surface associated LAMPs. Resting macrophages did
not express surface CD107a (data not shown). Neutrophils were
determined by their SSC
high, Gr-1
high, Ly6-G
+,M H CI I
2,
F480
2 phenotype. CD4
+ Tregs were determined by reactivity to
CD25 and FoxP3 GFP expression in the 129 FoxP3 GFP
reporter mice. Cells were acquired on a Cyan ADP Analyzer
(Beckman Coulter, Fullerton CA) and flow cytometry analysis
was performed using Flowjo software (Treestar Inc.). In Results,
where percentage of cell subsets is calculated within specific
populations, the specific population is gated and considered to be
100%, while cell subsets are expressed as a fraction thereof. For
example, in Figure 2E, the top left plot shows BS mononuclear
cells isolated from IVIG-treated HSV-infected mice at d6 pi.
The CD45
high infiltrating cells comprise 6.6% of total mononu-
clear cells. CD11b
+ monocytes therefore comprise 55% (3.6%
CD11b
+ 4 6.6% CD45
high) of total CD45
high infiltrating cells
within the BS.
Determination of BBB Integrity
To determine the integrity of the BBB after HSV corneal
infection, mice were injected i.p. with 10% sodium fluorescein
(Sigma Aldrich, PA). After 10 min, mice were bled and perfused
and the BS, brain and spinal cord collected and frozen on dry ice.
The organs were weighed and homogenized in 10% w/vol PBS.
Homogenates were treated with 15% TCA and extracted with
1.5 M NaOH. The supernatants were analyzed for fluorescence at
475 nm, and the amount of sodium fluorescein in sera and BS
were extrapolated from a standard curve. The following formula
was used to calculate the amount of sodium fluorescein in BS or
brain: (mg fluorescein in brain tissue/mg of protein)/(mg
fluorescein in sera/ml of blood) and the result was expressed as
fold increase in fluorescence in comparison to naı ¨ve mice [54].
Preparation and Purification of F(ab)2 and Fc Fragments,
Monomeric and Dimeric IVIG and Cu
64-Labeled
Monomeric IVIG
To prepare F(ab)2 and Fc fragments, IVIG was dialyzed into
PBS using a Mini Dialyzer cassette (10 kDa, Thermo Scientific,
Rockford, IL) prior to enzymatic cleavage with either Pepsin or
papain (Thermo Scientific) using the manufacturer’s protocol. The
reaction was stopped by spinning down the enzyme-linked beads
and the reaction mixture was dialyzed into PBS prior to
partitioning the Fc and F(ab)2 fragments using HPLC. The
F(ab)2 fragments retained antigen binding and neutralizing
activities. Aggregated and non-aggregated IgGs were separated
using HPLC, and these comprised primarily head-to-head dimers
and monomers of IgG, respectively. The non-aggregated fraction
of IVIG was collected based on size and the purity determined by
SDS PAGE electrophoresis. To label IVIG with radiolabeled
64Cu, IVIG was conjugated with DO3A-VS (1,4,7-tris(carbox-
ymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclododecane), a bi-
functional chelator, under Argon for 2 h at room temperature as
previously described [55]. Labeling with
64Cu was performed in
0.1 M ammonium citrate, pH 5.5 for 45 min at 43uC and the
reaction terminated by addition of 10 mM DTPA to achieve a
final concentration of 1 mM. The radiolabeled product was
purified on a size exclusion column. HSV infected or naı ¨ve mice
were injected with IVIG spiked with 50 ul of
64Cu-labeled IVIG
(50 ml) at 24 h pi. At 4–8 h intervals over a 48 h period, mice were
imaged with a small animal PET scanner (microPET R4,
Siemens/CTIMI, Knoxville, TN). At 44–48 h pi, animals were
euthanized and organs such as spleen, liver, brain, BS, trigeminal
ganglia, etc. were weighed and assayed for radioactivity using a
gamma counter. All image processing and analysis was performed
using standard microPET software [55].
Statistical Analysis
Graph Pad Prizm Software was used to analyze mortality data
by log rank (Mantel Cox) test, taking into account both time of
death and mortality.
Supporting Information
Figure S1 Effect of dose and time of IVIG administration on
protection. (A) 129 WT mice infected with HSV 17+ by corneal
scarification were given 3.75 mg IVIG i.p. at indicated times pi or
(B) different doses of IVIG at 24 h pi.
(TIF)
Figure S2 SNA lectin blotting to detect sIgG. S
+ IgG and S
2
IgG were purified from IVIG and HSV seronegative pooled serum
by affinity chromatography on SNA lectin columns and blotted for
reactivity to SNA lectin (top) or anti-human IgG (bottom).
(TIF)
Figure S3 Bio-distribution of
64Cu-labeled IVIG in HSV infected
129 WT mice and naı ¨ve mice. Mice injected i.p. with purified
64Cu-
labeled IgG at 24 h pi were sacrificed at 44 h after IgG infusion,
various tissues were dissected from infected and naı ¨ve mice and
radioactivity was determined by gamma counting. The average
percent injected activity dose per gram organ for uninfected and
infected mice was calculated after correcting for radio-decay.
(TIF)
Figure S4 CD45
high cells infiltrating the spinal cords of HSV
infected mice. CD45
high infiltrates (determined by flow cytometry)
in mice treated with IVIG or PBS at d6 and d8 pi.
(TIF)
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and IFN-c. Mononuclear cells isolated at d6 pi (A) or d14 pi (B)
from BS of HSV infected mice given PBS or IVIG were stimulated
with (blue dots) or without (red) PMA + ionomycin and analyzed
for intracellular IFN-cand IL-10 by flow cytometry. Percentages in
top row indicate percent of cells positive for cytokine expression
within CD45
high subset.
(TIF)
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